{"id":7490,"date":"2019-12-10T12:09:29","date_gmt":"2019-12-10T17:09:29","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=7490"},"modified":"2020-07-13T14:15:50","modified_gmt":"2020-07-13T18:15:50","slug":"fda-approves-gilenya-generic","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/","title":{"rendered":"FDA approves Gilenya generic"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">For nearly a decade, people with relapsing cases of multiple sclerosis (MS) had basically one treatment option: <\/span><a href=\"https:\/\/www.singlecare.com\/prescription\/gilenya\"><span style=\"font-weight: 400;\">Gilenya<\/span><\/a><span style=\"font-weight: 400;\">. It was the only FDA-approved medication for adults and children age 10 and older, until last week.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">On December 5, the U.S. Food and Drug Administration (FDA) <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generics-gilenya\"><span style=\"font-weight: 400;\">announced<\/span><\/a><span style=\"font-weight: 400;\"> approval for generic Gilenya, fingolimod, to HEC Pharm Co. Limited, Biocon Limited, and Sun Pharmaceutical Industries Limited.\u00a0<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What is Gilenya?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Manufactured by Novartis Pharmaceuticals Corporation, Gilenya was first approved by the FDA in 2010. It was the first oral treatment created for reducing relapses and slowing disease progression. In <\/span><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gilenya-treat-multiple-sclerosis-pediatric-patients\"><span style=\"font-weight: 400;\">2018<\/span><\/a><span style=\"font-weight: 400;\">, the FDA expanded its approval for the drug to include pediatric patients.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The<\/span><a href=\"https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/gilenya.pdf\"> <span style=\"font-weight: 400;\">currently recommended dosage<\/span><\/a><span style=\"font-weight: 400;\"> of Gilenya for adults and children who are 10 years or older and weigh at least 40 kg is one 0.5 mg capsule per day. Children who are at least 10 years old but weigh 40 kg or less should take one 0.25 mg capsule per day.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What is MS?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">MS is an autoimmune inflammatory disease, meaning the body\u2019s immune cells attack the fatty covering of nerve fibers, disrupting nerve impulses and causing symptoms like muscle weakness, fatigue, numbness or tingling, muscle spasms, difficulty walking, vision changes, and even bladder or bowel dysfunction. Many people experience cycles of relapses followed by remissions. Over time, it\u2019s harder to achieve complete remission after a flare-up, and the disease progresses.<\/span><\/p>\n<p><a href=\"https:\/\/www.gilenya.com\/c\/multiple-sclerosis\/how-it-works\"><span style=\"font-weight: 400;\">Gilenya<\/span><\/a><span style=\"font-weight: 400;\"> is the most commonly used treatment in these cases. It is thought to work by reducing the immune cells circulating in the body, thereby reducing the attacks on nerve cells that cause symptoms.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">How much does Gilenya cost?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Partially because of patent protections, the cost of Gilenya remained high\u2014an average price of<\/span> <span style=\"font-weight: 400;\">$8,211 for a 30-day supply of 0.5mg capsules.<\/span><span style=\"font-weight: 400;\"> Though, <\/span><a href=\"https:\/\/www.gilenya.com\/c\/ms-pill\/co-pay\"><span style=\"font-weight: 400;\">Novartis<\/span><\/a><span style=\"font-weight: 400;\"> says that most health insurance plans cover the medication, including 99% of people with commercial insurance and 96% of people with Medicaid or Medicare. Novartis also offers two co-pay support programs to assist with payment for the drug.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">These approvals are the first step toward generic competition, which could lower costs of this treatment.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cAddressing the challenges related to developing generics and promoting more generic competition is a key part of the FDA\u2019s Drug Competition Action Plan and the agency\u2019s efforts to help increase patient access to more affordable medications,\u201d the FDA <\/span><a href=\"http:\/\/s2027422842.t.en25.com\/e\/es?s=2027422842&amp;e=282006&amp;elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&amp;elq=e79b8752dd9f4af5a8063038ff8138ed&amp;elqaid=10520&amp;elqat=1\"><span style=\"font-weight: 400;\">statement<\/span><\/a> said<span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">When will generic Gilenya be available?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">It has not yet been announced when the three pharmaceutical manufacturers who received approval will begin selling the fingolimod (Gilenya generic) in the United States. No pricing structure is available yet, either.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>For nearly a decade, people with relapsing cases of multiple sclerosis (MS) had basically one treatment option: Gilenya. It was the only FDA-approved medication for adults and children age 10 and older, until last week. On December 5, the U.S. Food and Drug Administration (FDA) announced approval for generic Gilenya, fingolimod, to HEC Pharm Co. [&hellip;]<\/p>\n","protected":false},"author":65,"featured_media":6925,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4589,4114],"tags":[4141],"coauthors":[9482],"class_list":["post-7490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-info","category-news","tag-fda-approvals","wpautop"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA approves three applications for Gilenya generic<\/title>\n<meta name=\"description\" content=\"On Dec. 5, 2019 the U.S. Food and Drug Administration (FDA) announced approval for fingolimod, the generic form of Gilenya, a drug that treats MS.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approves Gilenya generic\" \/>\n<meta property=\"og:description\" content=\"Fingolimod is a drug that treats MS\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/\" \/>\n<meta property=\"og:site_name\" content=\"The Checkup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/singlecare\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-10T17:09:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-07-13T18:15:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2019\/11\/Blog_FDA_Approval_Stamp_Template_Blue.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jennifer Larson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SingleCare\" \/>\n<meta name=\"twitter:site\" content=\"@SingleCare\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jennifer Larson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/\"},\"author\":{\"name\":\"Dalene Rovenstine\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#\\\/schema\\\/person\\\/e0b184c53bd77faef796b4cd06f5713b\"},\"headline\":\"FDA approves Gilenya generic\",\"datePublished\":\"2019-12-10T17:09:29+00:00\",\"dateModified\":\"2020-07-13T18:15:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/Blog_FDA_Approval_Stamp_Template_Blue.png\",\"keywords\":[\"FDA approvals\"],\"articleSection\":[\"Drug Info\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/\",\"url\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/\",\"name\":\"FDA approves three applications for Gilenya generic\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/Blog_FDA_Approval_Stamp_Template_Blue.png\",\"datePublished\":\"2019-12-10T17:09:29+00:00\",\"dateModified\":\"2020-07-13T18:15:50+00:00\",\"description\":\"On Dec. 5, 2019 the U.S. Food and Drug Administration (FDA) announced approval for fingolimod, the generic form of Gilenya, a drug that treats MS.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/Blog_FDA_Approval_Stamp_Template_Blue.png\",\"contentUrl\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/Blog_FDA_Approval_Stamp_Template_Blue.png\",\"width\":1920,\"height\":1080,\"caption\":\"FDA approval stamp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/news\\\/fda-approves-gilenya-generic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA approves Gilenya generic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/\",\"name\":\"The Checkup, a health blog by SingleCare\",\"description\":\"Read the latest in prescription, wellness, and healthcare news\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#organization\",\"name\":\"SingleCare\",\"url\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/placeholderimage-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/wp-content\\\/uploads\\\/2020\\\/01\\\/placeholderimage-1.jpg\",\"width\":1200,\"height\":630,\"caption\":\"SingleCare\"},\"image\":{\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/singlecare\",\"https:\\\/\\\/x.com\\\/SingleCare\",\"https:\\\/\\\/www.instagram.com\\\/singlecare\\\/?hl=en\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/singlecare\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCd9kiPIjCQw95-2BHCYePKA\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/#\\\/schema\\\/person\\\/e0b184c53bd77faef796b4cd06f5713b\",\"name\":\"Dalene Rovenstine\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8eb4ee28d58da149dfed054c986673247c9cae421d5592d3938f5cc83f4b90a8?s=96&d=mm&r=g1d79055e970fe03b1322b6176470ae33\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8eb4ee28d58da149dfed054c986673247c9cae421d5592d3938f5cc83f4b90a8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8eb4ee28d58da149dfed054c986673247c9cae421d5592d3938f5cc83f4b90a8?s=96&d=mm&r=g\",\"caption\":\"Dalene Rovenstine\"},\"url\":\"https:\\\/\\\/www.singlecare.com\\\/blog\\\/author\\\/drovenst\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA approves three applications for Gilenya generic","description":"On Dec. 5, 2019 the U.S. Food and Drug Administration (FDA) announced approval for fingolimod, the generic form of Gilenya, a drug that treats MS.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/","og_locale":"en_US","og_type":"article","og_title":"FDA approves Gilenya generic","og_description":"Fingolimod is a drug that treats MS","og_url":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/","og_site_name":"The Checkup","article_publisher":"https:\/\/www.facebook.com\/singlecare","article_published_time":"2019-12-10T17:09:29+00:00","article_modified_time":"2020-07-13T18:15:50+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2019\/11\/Blog_FDA_Approval_Stamp_Template_Blue.png","type":"image\/png"}],"author":"Jennifer Larson","twitter_card":"summary_large_image","twitter_creator":"@SingleCare","twitter_site":"@SingleCare","twitter_misc":{"Written by":"Jennifer Larson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#article","isPartOf":{"@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/"},"author":{"name":"Dalene Rovenstine","@id":"https:\/\/www.singlecare.com\/blog\/#\/schema\/person\/e0b184c53bd77faef796b4cd06f5713b"},"headline":"FDA approves Gilenya generic","datePublished":"2019-12-10T17:09:29+00:00","dateModified":"2020-07-13T18:15:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/www.singlecare.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2019\/11\/Blog_FDA_Approval_Stamp_Template_Blue.png","keywords":["FDA approvals"],"articleSection":["Drug Info","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/","url":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/","name":"FDA approves three applications for Gilenya generic","isPartOf":{"@id":"https:\/\/www.singlecare.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#primaryimage"},"image":{"@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2019\/11\/Blog_FDA_Approval_Stamp_Template_Blue.png","datePublished":"2019-12-10T17:09:29+00:00","dateModified":"2020-07-13T18:15:50+00:00","description":"On Dec. 5, 2019 the U.S. Food and Drug Administration (FDA) announced approval for fingolimod, the generic form of Gilenya, a drug that treats MS.","breadcrumb":{"@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#primaryimage","url":"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2019\/11\/Blog_FDA_Approval_Stamp_Template_Blue.png","contentUrl":"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2019\/11\/Blog_FDA_Approval_Stamp_Template_Blue.png","width":1920,"height":1080,"caption":"FDA approval stamp"},{"@type":"BreadcrumbList","@id":"https:\/\/www.singlecare.com\/blog\/news\/fda-approves-gilenya-generic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.singlecare.com\/blog\/"},{"@type":"ListItem","position":2,"name":"FDA approves Gilenya generic"}]},{"@type":"WebSite","@id":"https:\/\/www.singlecare.com\/blog\/#website","url":"https:\/\/www.singlecare.com\/blog\/","name":"The Checkup, a health blog by SingleCare","description":"Read the latest in prescription, wellness, and healthcare news","publisher":{"@id":"https:\/\/www.singlecare.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.singlecare.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.singlecare.com\/blog\/#organization","name":"SingleCare","url":"https:\/\/www.singlecare.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.singlecare.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2020\/01\/placeholderimage-1.jpg","contentUrl":"https:\/\/www.singlecare.com\/blog\/wp-content\/uploads\/2020\/01\/placeholderimage-1.jpg","width":1200,"height":630,"caption":"SingleCare"},"image":{"@id":"https:\/\/www.singlecare.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/singlecare","https:\/\/x.com\/SingleCare","https:\/\/www.instagram.com\/singlecare\/?hl=en","https:\/\/www.linkedin.com\/company\/singlecare\/","https:\/\/www.youtube.com\/channel\/UCd9kiPIjCQw95-2BHCYePKA"]},{"@type":"Person","@id":"https:\/\/www.singlecare.com\/blog\/#\/schema\/person\/e0b184c53bd77faef796b4cd06f5713b","name":"Dalene Rovenstine","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/8eb4ee28d58da149dfed054c986673247c9cae421d5592d3938f5cc83f4b90a8?s=96&d=mm&r=g1d79055e970fe03b1322b6176470ae33","url":"https:\/\/secure.gravatar.com\/avatar\/8eb4ee28d58da149dfed054c986673247c9cae421d5592d3938f5cc83f4b90a8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8eb4ee28d58da149dfed054c986673247c9cae421d5592d3938f5cc83f4b90a8?s=96&d=mm&r=g","caption":"Dalene Rovenstine"},"url":"https:\/\/www.singlecare.com\/blog\/author\/drovenst\/"}]}},"_links":{"self":[{"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/posts\/7490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/comments?post=7490"}],"version-history":[{"count":0,"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/posts\/7490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/media\/6925"}],"wp:attachment":[{"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/media?parent=7490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/categories?post=7490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/tags?post=7490"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.singlecare.com\/blog\/wp-json\/wp\/v2\/coauthors?post=7490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}